RegeneRx Set To Begin Enrolling Phase 2 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome. The Company anticipates enrollment of the first patients on August 13th, and expects preliminary data from the study to be available in October 2011. The trial is a double-masked, placebo-controlled trial testing the safety and efficacy of RGN-259, the Company's proprietary preservative-free eye drops, against a placebo. Patients will receive RGN-259 or placebo twice daily for 30 days.

Full Story →